The purpose of the study is to compare the effectiveness of a new medicine with that of standard chemotherapy. The investigational drug being tested is Sofetabart Mipitecan (LY4170156). For participants with platinum-resistant disease, the new drug may be given alone and compared with the doctor’s choice of chemotherapy drugs such as carboplatin, paclitaxel, gemcitabine, topotecan or doxorubicin, or with Mirvetuximab Soravtansine. For those with platinum-sensitive disease, the new drug is combined with bevacizumab and compared with a standard platinum‑based two‑drug chemotherapy regimen plus bevacizumab.

Participants receive the study medicines through an IV infusion every few weeks and attend regular clinic visits where doctors perform physical examinations and imaging scans to check how the cancer is responding. Treatment continues until the cancer grows, side effects become unacceptable, or the study period ends, which may be several months for each participant.

The study has two main parts. The first part aims to find the right dose of ubamatamab when given alone or with cemiplimab by checking how safe it is and how the body processes the medication. The second part looks at how well these treatments work in shrinking or controlling the cancer. For patients with ovarian, fallopian tube, or primary peritoneal cancer, they must have received at least one previous treatment with platinum-based chemotherapy and have cancer that has returned or is no longer responding to treatment. For patients with endometrial cancer, they must have previously received treatment with a type of immune therapy and platinum-based chemotherapy, and their cancer must show a certain protein marker called MUC16 in at least one quarter of the tumor cells.

During the study, patients will receive their assigned treatment and be monitored regularly for side effects and to see how their cancer responds. Doctors will use scans and blood tests to check if the cancer is shrinking, staying the same, or growing. The study will also measure how the treatment affects quality of life and daily functioning through questionnaires. Blood samples will be taken to measure the amount of medication in the body and to check if the body develops any reaction to the medications. The study will continue until enough information is gathered about the safety and effectiveness of these treatments.

The treatment involves receiving TORL-1-23 through an intravenous infusion (given directly into a vein). During the study, participants may also receive pegfilgrastim, a supportive medication that helps the body produce white blood cells after treatment. The study treatment may continue for up to 24 months, depending on how well participants respond to the therapy.

The study medication TORL-1-23 is designed to specifically target cancer cells that have the CLDN6 protein on their surface. It works by delivering a cancer-fighting substance directly to these cells while aiming to minimize effects on healthy cells. This targeted approach represents a new way of treating these types of cancer that no longer respond to standard platinum-based treatments.

The study involves two main groups of patients. The first group will receive the medication according to different dosing schedules, while patients with moderate liver problems will be studied separately to find the right starting dose for them. During treatment, patients will receive the medication every three weeks as part of a 21-day cycle. The study will also use prednisolone acetate eye drops and lubricating eye drops as supportive care.

The research team will monitor patients for treatment effectiveness and any side effects, particularly paying attention to eye-related effects. They will track how the cancer responds to treatment through regular medical examinations and imaging tests. The study will also measure how long the treatment keeps working and how long patients survive after starting the treatment.

The purpose of this study is to evaluate how effective this combination of medications is in treating the specified types of cancer. Participants in the study will receive these medications and will be monitored over time to assess their response to the treatment. The study will track the progression of the disease and any changes in the participants’ health. The trial aims to gather information on how well the treatment works and any side effects that may occur.

Throughout the study, participants will undergo regular check-ups and assessments to monitor their health and the impact of the treatment. The study is designed to provide valuable insights into the potential benefits and risks of using relacorilant in combination with nab-paclitaxel and bevacizumab for treating these advanced cancers. This research could contribute to developing more effective treatment options for patients with these types of cancer in the future.

After the initial chemotherapy, patients will be divided into two groups. One group will receive a medication called niraparib alone, while the other group will receive niraparib combined with bevacizumab. Niraparib is taken as a capsule by mouth, while bevacizumab is given through an intravenous infusion. The purpose of this study is to determine if adding bevacizumab to niraparib treatment leads to better results than using niraparib alone.

The study will monitor how long patients remain without their cancer getting worse. Patients will receive regular medical examinations and tests throughout the study period. The treatment may continue for up to 36 months, depending on how well patients respond to the therapy and whether they experience any side effects.

Participants in the study will receive either the combination of relacorilant and nab-paclitaxel or nab-paclitaxel by itself. The treatment will be given over a period of 28 days, and the study will monitor how the cancer responds to the treatment. The study aims to see if the combination treatment can help control the cancer better than nab-paclitaxel alone. The study will also look at how long patients live without the cancer getting worse and other measures of how well the treatment works.

This trial is important for understanding if adding relacorilant to nab-paclitaxel can provide a new option for patients with this challenging type of cancer. The study will help determine if the combination treatment can improve outcomes for patients compared to the standard treatment with nab-paclitaxel alone. Participants will be closely monitored throughout the study to ensure their safety and to gather important information about the treatment’s effects.

The purpose of the study is to determine the best dose of IMGN151 that can be safely given to patients and to see how well it works in treating these cancers. The study will be conducted in two main phases. In the first phase, different doses of IMGN151 will be tested to find the safest and most effective dose. In the second phase, the chosen dose will be given to more patients to further assess its effectiveness. Throughout the study, participants will receive IMGN151 through an intravenous infusion, which means the medication will be delivered directly into the bloodstream through a vein.

Participants in the study will be closely monitored for any side effects and to see how their cancer responds to the treatment. The study aims to provide valuable information about the potential benefits and risks of IMGN151 for women with these specific types of recurrent cancers. This research is important for developing new treatment options that could improve outcomes for patients facing these challenging conditions.

The purpose of this study is to continue providing treatment to patients who have completed a previous cancer study with Olaparib and are still benefiting from it. The study aims to ensure the safety and tolerability of the ongoing treatment. Patients will continue to receive Olaparib if they are judged by their doctor to be benefiting from the treatment. The study will monitor the patients’ health and any side effects that may occur during the treatment period.

Participants in this study will take Olaparib tablets orally, with the treatment period lasting up to 123 days. The study will keep track of any serious side effects or important medical events that happen up to 30 days after the last dose of the study drug. This trial is designed to help patients who are already experiencing positive effects from Olaparib to continue their treatment safely.

The purpose of the study is to evaluate how well the combination of nemvaleukin alfa and pembrolizumab works compared to chemotherapy in improving the survival of patients with this type of cancer. Participants in the study will receive either the new drug combination or chemotherapy, which may include drugs like topotecan hydrochloride, gemcitabine hydrochloride, paclitaxel, or doxorubicin hydrochloride. The treatment will be given through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein.

Throughout the study, participants will have regular visits to monitor their health and the effects of the treatment. The study aims to gather information on overall survival, how long patients live without the cancer getting worse, and the response of the cancer to the treatment. Safety will also be closely monitored by checking for any side effects or changes in health. The study is expected to continue until 2027, providing valuable insights into the effectiveness of this new treatment approach for patients with platinum-resistant ovarian cancer.

The purpose of this study is to better understand how these medications can benefit patients with these types of cancers after they have received standard first-line treatment. The study will explore the status of a condition called HRD, which stands for homologous recombination deficiency, a situation where cancer cells are less able to repair DNA damage. Participants will receive Olaparib in combination with Bevacizumab to see if this combination can provide additional benefits. The study is non-randomized and open-label, meaning all participants will know which treatment they are receiving, and it is designed to gather information prospectively, or looking forward in time.

Participants in the study will follow a treatment plan that includes taking Olaparib orally and receiving Bevacizumab through intravenous use. The study will last for a period of time, with regular monitoring to assess the effects of the treatment. The main goal is to determine how well the HRD status can be identified using different tests and to see how this status affects the treatment outcomes. The study will also look at the progression-free survival and overall survival of participants, as well as any side effects experienced during the trial. The trial is expected to continue until 2028.

Participants in the study will receive either the new treatment combination or a standard treatment, which may include drugs like Gemcitabine, Paclitaxel, Doxorubicin, Rucaparib, Olaparib, or Niraparib. Some participants may receive a placebo. The study will monitor the time it takes for the cancer to progress or for the patient to pass away, whichever happens first. This is known as progression-free survival. The study will also look at overall survival, which is the time from the start of the study until death from any cause, and the response rate, which measures how well the cancer responds to the treatment.

The trial will last for several years, and participants will be closely monitored throughout the study. The study aims to provide valuable information about the potential benefits and risks of using Mirvetuximab soravtansine with Carboplatin in treating recurrent ovarian cancer. This research could lead to new treatment options for patients with this type of cancer.

The purpose of this study is to evaluate how well Pembrolizumab works in patients with these specific types of cancer. The study will look at how long patients live after receiving the treatment, which is referred to as overall survival. Additionally, the study will monitor other aspects such as the side effects of the treatment, how the cancer responds to the treatment, how long patients live without the cancer getting worse, and the overall quality of life of the patients during the study.

Participants in the study will receive Pembrolizumab as a single treatment over a period of up to 24 months. The study is designed to gather information on the effectiveness and safety of Pembrolizumab in treating these cancers. By participating in this study, researchers hope to gain valuable insights that could help improve treatment options for patients with these challenging types of cancer in the future.

The purpose of the study is to evaluate how these treatments affect the overall survival of patients, which means the length of time patients live after starting the treatment. Participants in the study will be randomly assigned to receive either the niraparib-dostarlimab combination or one of the chemotherapy options. The chemotherapy options may include medications such as doxorubicin hydrochloride, gemcitabine hydrochloride, bevacizumab, topotecan, or paclitaxel. These are all anti-cancer agents that work in different ways to stop the growth of cancer cells.

The study will take place over a period of up to 24 months, during which participants will receive their assigned treatment and be monitored regularly. The goal is to determine which treatment option provides the best outcomes for patients with these specific types of cancer. Participants will receive either the active treatment or a placebo, and their health will be closely observed throughout the study to ensure safety and effectiveness.

Participants in the study will be divided into different groups to receive either the medications or a placebo. The study will compare the effects of taking Rucaparib alone, Rucaparib combined with Nivolumab, or a placebo. The trial will monitor the progression of the disease and overall survival rates among participants. The study aims to determine if these treatments can help maintain the positive effects of the initial chemotherapy and delay the progression of the cancer.

The trial will be conducted over several years, with participants receiving treatment and being monitored for any changes in their condition. The study will use specific criteria to evaluate the effectiveness of the treatments, such as the time it takes for the disease to progress or for any adverse effects to occur. The results will help determine the potential benefits of using Rucaparib and Nivolumab as part of a long-term treatment plan for patients with advanced ovarian cancer.

The purpose of this study is to compare the effectiveness of different combinations of these medications in patients with advanced ovarian, primary peritoneal, and Fallopian tube cancer. The study will explore how well these treatments work based on the Homologous Recombination Deficient (HRD) status of the patients, which is a specific characteristic of the cancer cells that can affect how they respond to treatment. The trial will begin with a phase to determine the safest dose of the combination of Rucaparib and Bevacizumab, followed by a phase to compare the progression-free survival of patients receiving different treatment combinations.

Participants in the study will receive one of the following treatment combinations: Carboplatin, Paclitaxel, and Bevacizumab; Carboplatin, Paclitaxel, Bevacizumab, and Rucaparib; or Carboplatin, Paclitaxel, and Rucaparib. The study will monitor the patients over time to assess how long they live without the cancer getting worse. The trial aims to provide valuable information on the best treatment options for patients with these types of cancer, based on their HRD status.

Participants in the study will undergo one of two types of surgeries: Primary Debulking Surgery (PDS) or Interval Debulking Surgery (IDS). These surgeries are performed to remove as much of the cancer as possible. After the surgery, some patients will receive the HIPEC treatment, while others will receive standard care without HIPEC. The study will compare the outcomes of these two groups to see if the HIPEC treatment is more effective. The study will also monitor the overall survival of patients and any side effects they may experience during the treatment.

The trial will follow participants over a period of time to assess their disease-free survival (DFS), which means the length of time they live without the cancer returning. Researchers will also evaluate the overall quality of life of the participants using questionnaires. The study aims to provide valuable information on whether adding HIPEC to standard surgical treatment can improve outcomes for patients with ovarian cancer.

Participants in the study will receive their treatments through an infusion, which means the medication is given directly into a vein. The study will follow patients over a period of time to monitor their health and the progression of their cancer. The main goal is to determine if the addition of Oregovomab can improve the time patients live without their cancer progressing, which is known as progression-free survival. The study will also look at overall survival, which is the length of time patients live after starting the treatment, and any side effects that may occur.

This trial is designed to provide important information about the potential benefits of Oregovomab when used alongside standard chemotherapy for patients with advanced ovarian cancer. By comparing the two groups, researchers hope to find out if this new treatment can offer better outcomes for patients facing these challenging conditions.

The purpose of this study is to determine if pembrolizumab, when used in combination with chemotherapy, can help patients with this type of cancer live longer without the disease getting worse. Participants in the study will receive the treatment and be monitored over a period of time to see how well the cancer responds. The study will also look at the safety of the treatment and how it affects the quality of life for those involved.

Throughout the study, participants will receive pembrolizumab through an intravenous infusion, which means the medication is given directly into a vein. The study will last for several months, and participants will have regular check-ups to monitor their health and the progress of the treatment. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatment. The study aims to provide valuable information on the potential benefits of pembrolizumab for patients with low-grade serous ovarian cancer.

Participants in the study will receive ZN-c3 in the form of film-coated tablets taken orally. The study will be conducted in two parts. In the first part, the focus will be on determining the safety and how well patients can tolerate ZN-c3. The second part will investigate the medication’s ability to reduce or eliminate the cancer. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of ZN-c3.

The study will take place over a period of time, with regular check-ups and assessments to monitor the participants’ health and the cancer’s response to the treatment. The goal is to gather information that could lead to better treatment options for patients with this type of cancer. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and well-being.

The purpose of the study is to determine if taking niraparib after three cycles of chemotherapy is as effective as taking it after six cycles. The study will involve patients receiving either three or six cycles of chemotherapy, followed by maintenance treatment with niraparib. Some patients may receive a placebo instead of niraparib to compare the outcomes. The study aims to see if the shorter treatment duration can provide similar benefits in preventing cancer from returning.

Participants in the study will be monitored over time to assess their health and any side effects from the treatments. The study will also look at how long patients live without the cancer coming back and their overall survival rates. The trial will help determine the best approach to using niraparib in treating these types of cancer, potentially offering a more efficient treatment option for patients in the future.

The purpose of the study is to see how well MORAb-202 works compared to the other chemotherapy treatments. Participants in the study will receive either the new treatment or one of the standard chemotherapy options, which may include drugs like Caelyx (containing doxorubicin hydrochloride), paclitaxel, or topotecan. These medications are given through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein.

The study will follow participants over a period of time to monitor their response to the treatment and any side effects they may experience. The main goal is to determine the effectiveness of MORAb-202 in treating this type of cancer and to assess the safety of the treatment. Participants will be closely monitored by healthcare professionals throughout the study to ensure their well-being and to gather important information about the treatment’s impact on their cancer.

The purpose of the study is to evaluate how well Raludotatug Deruxtecan works compared to other treatments that doctors might choose, such as paclitaxel, doxorubicin hydrochloride, liposomal, gemcitabine hydrochloride, or topotecan. These are all medications that are commonly used to treat cancer. The study will involve participants receiving these treatments through an intravenous infusion, which means the medication is given directly into a vein.

Participants in the study will be randomly assigned to receive either Raludotatug Deruxtecan or one of the other treatments. The study will take place over a period of up to 24 months. During this time, participants will have regular visits to monitor their health and the effects of the treatment. The study aims to provide more information about the effectiveness and safety of Raludotatug Deruxtecan for treating these types of cancer.

In addition to bevacizumab, other medications used in this study include olaparib, carboplatin, and paclitaxel. Olaparib is taken orally in the form of a tablet, while carboplatin and paclitaxel are given as infusions. The study will involve several groups of patients who will receive different combinations of these medications, including a placebo group. The treatment period for each patient can last up to 76 weeks, depending on the specific medications they receive.

The main goal of the study is to see if the lower dose of bevacizumab is as effective as the standard dose in preventing the progression of the disease. Throughout the study, researchers will monitor the patients’ response to the treatment and any side effects they may experience. The study will also assess the overall quality of life of the participants using standardized questionnaires. This research is important for understanding how to best use bevacizumab and other medications in treating these types of cancer.

The purpose of this study is to compare the effectiveness of the combination of mirvetuximab soravtansine and bevacizumab with bevacizumab alone in maintaining the health of patients who have not shown disease progression after receiving platinum-based chemotherapy. Patients will be randomly assigned to receive either the combination treatment or bevacizumab alone. The study will monitor the patients over a period to assess how long they remain free from cancer progression. This is known as progression-free survival, which is a measure of how long patients live without the cancer getting worse.

Participants in the study will receive the treatments as an infusion, which means the medication is delivered directly into the bloodstream through a vein. The study will also involve regular check-ups and assessments to monitor the patients’ health and any side effects they may experience. The trial aims to provide valuable information on whether the combination of mirvetuximab soravtansine and bevacizumab offers better outcomes for patients compared to bevacizumab alone. This research could potentially lead to improved treatment options for individuals with these types of cancers.

The purpose of the study is to evaluate whether adding MK-4830 to the standard treatment of Pembrolizumab and chemotherapy can lead to a greater reduction in cancer-related DNA in the blood. Participants will receive these treatments over a period of time, with some receiving a placebo instead of MK-4830. The study will monitor changes in the levels of cancer-related DNA in the blood, as well as the overall response to the treatment, including any side effects experienced by participants.

Throughout the study, participants will undergo regular assessments to track their response to the treatment. This includes measuring changes in cancer-related DNA and evaluating the effectiveness of the treatment in reducing cancer cells. The study aims to provide valuable information on whether the addition of MK-4830 can improve outcomes for patients with these types of cancer.

The purpose of the study is to evaluate how well the combination of Carboplatin and Mirvetuximab Soravtansine works in treating these cancers. Initially, patients will receive both Carboplatin and Mirvetuximab Soravtansine together. After this phase, patients will continue treatment with Mirvetuximab Soravtansine alone. The study aims to see if this treatment approach can help control the cancer in patients who have shown sensitivity to platinum-based chemotherapy in the past.

Participants in the study will receive the treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor the response of the cancer to the treatment over time. This trial is open-label, meaning both the researchers and participants know which treatments are being administered. The study will help determine the effectiveness of this treatment combination in managing these specific types of cancer.

The purpose of this study is to determine the best dose of these medications when used together and to evaluate how well they work in treating the cancers mentioned. The study is divided into two phases: the Dose Escalation Phase and the Dose Expansion Phase. In the Dose Escalation Phase, researchers will focus on finding the safest and most effective dose of the medications. In the Dose Expansion Phase, they will look at how well the treatment works in a larger group of patients. Participants in the study may receive either the combination of REGN5668 with Cemiplimab or REGN5668 with REGN4018.

Throughout the study, participants will receive the medications through an intravenous infusion, which means the drugs are given directly into a vein. The study will monitor the participants for any side effects and measure how the cancer responds to the treatment. The trial aims to provide valuable information on the potential benefits of these new treatment combinations for patients with these specific types of cancer.

The study is designed to determine if mirvetuximab soravtansine works better than standard chemotherapy treatments. The main goal is to measure how long patients live without their cancer getting worse. The study will also look at how well patients respond to treatment, overall survival time, quality of life, and any side effects that may occur.

Participants will be randomly assigned to receive either mirvetuximab soravtansine or one of the standard chemotherapy medications through intravenous infusion. The treatment will continue for several months, with regular check-ups to monitor the cancer’s response to treatment and any side effects. The study is expected to run until mid-2025.